6667 Stock Overview
A genetic testing platform company, provides consumer genetic testing and cancer screening services in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Mega Genomics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$7.70 |
| 52 Week High | HK$12.40 |
| 52 Week Low | HK$7.35 |
| Beta | 1.44 |
| 1 Month Change | 0.52% |
| 3 Month Change | -5.75% |
| 1 Year Change | -1.28% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -57.22% |
Recent News & Updates
Shareholders Will Be Pleased With The Quality of Mega Genomics' (HKG:6667) Earnings
Oct 03
Returns On Capital Signal Tricky Times Ahead For Mega Genomics (HKG:6667)
Aug 28Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Recent updates
Shareholders Will Be Pleased With The Quality of Mega Genomics' (HKG:6667) Earnings
Oct 03Returns On Capital Signal Tricky Times Ahead For Mega Genomics (HKG:6667)
Aug 28Some Investors May Be Worried About Mega Genomics' (HKG:6667) Returns On Capital
May 03Calculating The Intrinsic Value Of Mega Genomics Limited (HKG:6667)
Feb 20Mega Genomics Limited's (HKG:6667) Share Price Could Signal Some Risk
Aug 12A Look At The Fair Value Of Mega Genomics Limited (HKG:6667)
Nov 07Shareholder Returns
| 6667 | HK Healthcare | HK Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | -0.5% |
| 1Y | -1.3% | -17.8% | 19.9% |
Return vs Industry: 6667 exceeded the Hong Kong Healthcare industry which returned -17.8% over the past year.
Return vs Market: 6667 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 6667 volatility | |
|---|---|
| 6667 Average Weekly Movement | 8.1% |
| Healthcare Industry Average Movement | 8.3% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 6667 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6667's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 214 | n/a | www.megagenomics.cn |
Mega Genomics Limited, a genetic testing platform company, provides consumer genetic testing and cancer screening services in China. It offers general testing services, including brain health assessment package, a service that assesses the risk of various related diseases, including Alzheimer’s disease; alimentation capability assessment package, a service that assesses the risk of developing hyperhomocysteinemia; Parkinson’s disease risk assessment; full-scale cancer risk assessment packages; and cardiovascular and cerebrovascular disease risk assessment packages. The company also provides advanced testing services, such as hereditary breast cancer/ovarian cancer genetic testing; Septin9 colorectal cancer screening test; RNF180/Septin9 gastric cancer screening test; and telomere length genetic testing that assesses the cell age and aging rate of a person.
Mega Genomics Limited Fundamentals Summary
| 6667 fundamental statistics | |
|---|---|
| Market cap | HK$1.77b |
| Earnings (TTM) | HK$33.99m |
| Revenue (TTM) | HK$170.21m |
52.0x
P/E Ratio10.4x
P/S RatioIs 6667 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6667 income statement (TTM) | |
|---|---|
| Revenue | CN¥159.71m |
| Cost of Revenue | CN¥67.10m |
| Gross Profit | CN¥92.62m |
| Other Expenses | CN¥60.73m |
| Earnings | CN¥31.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.14 |
| Gross Margin | 57.99% |
| Net Profit Margin | 19.97% |
| Debt/Equity Ratio | 3.3% |
How did 6667 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 08:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Mega Genomics Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Haoyuan Zhang | China Merchants Securities (HK) Co., Ltd |
| Fangqi Dai | China Merchants Securities (HK) Co., Ltd |